By: IPP Bureau
Last updated : November 10, 2025 11:04 am
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International Limited has reported consolidated financial results for the period ended September 30, 2025.
Syngene International has posted net profit of Rs. 67.1 crore for the period ended September 30, 2025 as against net profit of Rs. 86.7 crore for the period ended June 30, 2025. The company posted net profit of Rs. 106.1 crore for the period ended September 30, 2024.
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025 as compared to Rs. 892.2 crore during the period ended June 30, 2025. The company reported total income of Rs. 907.5 crore during the period ended September 30, 2024.
For the Half Year ended September 30, 2025, Syngene International has reported total income of Rs. 1,818.2 crore as compared to Rs. 1,715.3 crore during the 6 months period ended September 30, 2024.
The company has posted net profit of Rs. 153.8 crore for the 6 months period ended September 30, 2025 as against net profit of Rs. 181.8 crore for the 6 months period ended September 30, 2024.
Commenting on the performance, Peter Bains, Managing Director and CEO, Syngene International Limited, said: “Our Q2 performance was driven by solid growth in research services, which offset the anticipated inventory correction in biologics manufacturing. We are maintaining our full-year revenue guidance for FY26.
During the quarter, we secured our first global Phase III clinical trial contract from a U.S.-based biotech company, covering patient recruitment across sites in the U.S. and India. In line with our strategy to expand into new modalities, we are establishing a new GMP bioconjugation suite at our Bengaluru biologics facility. This will enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), positioning Syngene among a select group of CRDMOs with full-service ADC capabilities.
We are also encouraged by early signs of improvement in the U.S. biotech funding environment and remain agile in adapting to evolving industry trends.”
Deepak Jain, Chief Financial Officer, Syngene International Limited, added: “Our strong balance sheet and net cash position give us the flexibility to invest in strategic priorities that support long-term growth. The company continues to invest in dedicated facilities for peptides and ADCs, enhancing our presence in emerging biologics modalities.
With diversified service offerings across the value chain and available manufacturing capacity, Syngene is well-positioned to capture future growth opportunities. We are maintaining our EBITDA and PAT margin guidance for the full year.”